experienced a 4% decline in share price following a notice of non-compliance from Health Canada for its Abbreviated New Drug Application (ANDA) for Semaglutide, a weight management medication. The setback impacts the company's significant investments in infrastructure for Semaglutide and its plans to be a market leader. This incident is part of a broader trend of regulatory challenges faced by Indian pharmaceutical companies in complex drug applications. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.